Placing medical devices on the market and keeping them there is now about much more than technical documentation and a quality system. The EU Medical Device Regulation (MDR) has shifted the emphasis strongly toward clinical evaluation. Manufacturers must continuously demonstrate that their device is safe, achieves its intended performance, delivers clinical benefit, and has an acceptable benefit-risk ratio, both before market entry and throughout its entire lifecycle.
It is worth starting this work already at the design stage. The clinical evaluation plan (CEP), risk management, and usability engineering go hand in hand, because they are driven by the same inputs: intended purpose, target population, and clinical claims. Well planned is half done. Fixing gaps that are discovered afterward almost always costs more than careful planning at the outset.
The clinical expert plays a key role in this work. They combine medical understanding, systematic literature review, data analysis, and regulatory requirements into one coherent whole.
Why clinical expertise is needed
The MDR no longer accepts old data as is, or loose equivalence arguments. Notified Bodies (NBs) scrutinize clinical evaluations ever more critically, and shortcomings often show up as delays, additional questions, or even refusal of a certificate. Manufacturers of Class I devices must also perform a clinical evaluation, even though a notified body does not assess it. A well-planned clinical evaluation:
- speeds up conformity assessment
- reduces surprises in audits and assessments
- ensures that claims made about the device are justified by evidence
- lays the foundation for post-market clinical follow-up (PMCF) and periodic safety update reports (PSUR) throughout the lifecycle
- protects the company from later safety or performance problems
The clinical expert’s task is to build an argument that withstands scrutiny from authorities and the notified body.
The most common pitfalls manufacturers fall into
Many companies underestimate the scope and difficulty of the work that clinical evaluation requires. The most typical challenges are:
1. Planning the clinical strategy too late
Clinical evidence is only considered once the technical documentation is already well advanced. By then, opportunities to collect new data or design a necessary clinical investigation are limited. The device and its claims have already been locked, and the clinical evaluation has to justify them with whatever data happens to be available. The clinical evaluation plan (CEP) is drawn up before the clinical evaluation report (CER), not afterward to match it.
2. Insufficient or outdated clinical data
Legacy devices’ old CERs often fail to meet MDR requirements. Literature reviews are incomplete, the state-of-the-art analysis is superficial, or the equivalence justification does not withstand critical examination. In addition, for Class III and implantable devices, equivalence requires a contract that gives full access to the technical documentation of the comparator device.
3. A weak link between risk management, usability, and clinical evaluation
The ISO 14971 process, usability work, and clinical evaluation too often live in separate silos. The acceptability of residual risks is not based on sufficient clinical evidence.
4. PMCF remains on paper
Many manufacturers produce a PMCF plan, but its implementation, data collection, and reporting remain inadequate. This comes back to haunt them in the next CER update or PSUR. On the other hand, a heavy PMCF study is not always needed: a lighter approach or a documented justification may suffice.
5. Lack of in-house expertise
Few manufacturers have an in-house clinical expert with both a medical background and in-depth knowledge of the MDR and the MDCG guidance that interprets it. External support often arrives only in a crisis, when costs and schedule pressure are already high.
How we help
Our consulting team has strong clinical expertise integrated with regulatory and quality work. Among other things, we support our clients with:
- planning clinical evaluation at the very start of product development, together with risk management and usability work
- drafting and updating the clinical evaluation plan and report (CEP/CER)
- systematic literature reviews and state-of-the-art analyses
- building the PMCF strategy, plan, and reporting
- clinical evidence gap analyses and recommendations for action
- preparing the summary of safety and clinical performance (SSCP)
- responding to notified body clinical questions
- supporting the design of clinical investigations when needed
If you are updating existing CER documents, planning a new product, or preparing for a notified body assessment, get in touch. We will help you identify critical points early and build a solution that moves your project forward without unnecessary delays. The earlier clinical evaluation is planned, the fewer surprises and costs you will face later.
